Obstet Gynecol Sci.  2018 Sep;61(5):584-589. 10.5468/ogs.2018.61.5.584.

Effect of tibolone on the survival of early stage cervical adenocarcinoma patients

Affiliations
  • 1Department of Obstetrics and Gynecology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. leekwbm@naver.com

Abstract


OBJECTIVE
Gynecologic oncologists are uncertain about the safety of tibolone application in cervical adenocarcinoma (AC) patients. This study examined the possible adverse effects of tibolone on the survival of cervical AC patients.
METHODS
Medical records of 70 cervical AC patients with International Federation of Gynecology and Obstetrics stages IA to IB were reviewed. A bilateral salpingo-oophorectomy was performed in all patients, and survival outcomes between tibolone users (n=38) and non-users (n=32) were compared.
RESULTS
A comparison of the tibolone users with non-users revealed similar clinicopathological variables. Progression-free survival (P=0.34) and overall survival (P=0.22) were similar in the users and non-users. The risks of progression (hazard ratio [HR], 1.71; 95% confidence interval [CI], 0.46-6.37; P=0.43) and death (HR, 1.59; 95% CI, 0.06-45.66; P=0.79) were also similar in both groups.
CONCLUSION
Tibolone has no adverse effect on the survival of cervical AC patients and can be administered safely to this population. These findings may be helpful in improving the quality of life of cervical AC patients.

Keyword

Uterine cervical neoplasm; Adenocarcinoma; Tibolone; Prognosis; Survival
Full Text Links
  • OGS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr